Genetics

Cathie Wood-led Ark Investment Management on Friday raised its stake in clinical stage genetics medicine company Verve Therapeutics Inc (NASDAQ: VERV) via two of its exchange-traded funds. Together, the flagship ARK Innovation ETF (NYSE: ARKK) and the ARK Genomic Revolution ETF (NYSE: ARKG) bought...

Genetic testing company 23andMe Holding Co. (NASDAQ: ME) took the unconventional route of a SPAC deal to go public, and the stock hasn't gained much traction since it began trading on June 17, 2021. The new year saw the company announcing its diversification into drug development. Will this...

The bullish case for Applied Genetic Technologies Corp (NASDAQ: AGTC), a nano-cap biotech conducting human clinical trials of adeno-associated virus-based gene therapies, can be made on the basis of an encouraging pipeline and valuation reasons, according to Wells Fargo. The Analyst Wells Fargo...